Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5322 ARTÍCULOS , VIENDO DEL 1681 AL 1695

Transsulfuration pathway: a targeting neuromodulator in Parkinson's disease

Corona-Trejo A, Gonsebatt ME, Trejo-Solis C, Campos-Peña V, Quintas-Granados LI, Villegas-Vázquez EY, Daniel Reyes-Hernández O, Hernández-Abad VJ, Figueroa-González G, Silva-Adaya D.

Rev Neurosci. 2023 Jul 7;34(8):915-932. doi: 10.1515/revneuro-2023-0039. Print 2023 Dec 15.

An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease

Jing XZ, Yuan XZ, Luo X, Zhang SY, Wang XP.

Curr Neuropharmacol. 2023;21(8):1806-1826. doi: 10.2174/1570159X20666220222150811.

A Concise Review of Common Plant-derived Compounds as a Potential Therapy for Alzheimer's Disease and Parkinson's Disease: Insight into Structure-Activity-Relationship

Nishal S, Phaugat P, Bazaad J, Dhaka R, Khatkar S, Khatkar A, Khayatkashani M, Alizadeh P, Haghighi SM, Mehri M, Kashani HRK.

CNS Neurol Disord Drug Targets. 2023;22(7):1057-1069. doi: 10.2174/1871527321666220614110616.

Neuroprotective Potential and Underlying Pharmacological Mechanism of Carvacrol for Alzheimer's and Parkinson's Diseases

Javed H, Mohamed Fizur NM, Jha NK, Ashraf GM, Ojha S.

Curr Neuropharmacol. 2023;21(6):1421-1432. doi: 10.2174/1570159X21666221223120251.

DNA Methylation Signature of Aging: Potential Impact on the Pathogenesis of Parkinson's Disease

Yazar V, Dawson VL, Dawson TM, Kang SU.

J Parkinsons Dis. 2023;13(2):145-164. doi: 10.3233/JPD-223517.

A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn ("line 61") Mice

Richter F, Stanojlovic M, Käufer C, Gericke B, Feja M.

Neurotherapeutics. 2023 Jan;20(1):97-116. doi: 10.1007/s13311-022-01338-0. Epub 2023 Jan 30.

Oscillatory beta dynamics inform biomarker-driven treatment optimization for Parkinson's disease

Radcliffe EM, Baumgartner AJ, Kern DS, Al Borno M, Ojemann S, Kramer DR, Thompson JA.

J Neurophysiol. 2023 Jun 1;129(6):1492-1504. doi: 10.1152/jn.00055.2023. Epub 2023 May 17.

The role of sphingosine-1-phosphate in the development and progression of Parkinson's disease

Wang W, Zhao Y, Zhu G.

Front Cell Neurosci. 2023 Dec 21;17:1288437. doi: 10.3389/fncel.2023.1288437. eCollection 2023.

Lactoferrin: neuroprotection against Parkinson's disease and secondary molecule for potential treatment

Eker F, Bolat E, Pekdemir B, Duman H, Karav S.

Front Aging Neurosci. 2023 Sep 5;15:1204149. doi: 10.3389/fnagi.2023.1204149. eCollection 2023.

The dilemma between milestones of progression versus clinical scales in Parkinson's disease

Greenland JC, Camacho M, Williams-Gray CH.

Handb Clin Neurol. 2023;192:169-185. doi: 10.1016/B978-0-323-85538-9.00010-9.

Vitamin D and neurodegenerative diseases

Wang W, Li Y, Meng X.

Heliyon. 2023 Jan 12;9(1):e12877. doi: 10.1016/j.heliyon.2023.e12877. eCollection 2023 Jan.

Pharmacological Treatment of Tremor in Parkinson's Disease Revisited

Pirker W, Katzenschlager R, Hallett M, Poewe W.

J Parkinsons Dis. 2023;13(2):127-144. doi: 10.3233/JPD-225060.

Neuropathology of incidental Lewy body & prodromal Parkinson's disease

Koeglsperger T, Rumpf SL, Schließer P, Struebing FL, Brendel M, Levin J, Trenkwalder C, Höglinger GU, Herms J.

Mol Neurodegener. 2023 May 12;18(1):32. doi: 10.1186/s13024-023-00622-7.

The Crucial Roles of Pitx3 in Midbrain Dopaminergic Neuron Development and Parkinson's Disease-Associated Neurodegeneration

Wang X, Chen X, Liu G, Cai H, Le W.

Int J Mol Sci. 2023 May 11;24(10):8614. doi: 10.3390/ijms24108614.

A Research Update on Exendin-4 as a Novel Molecule Against Parkinson's Disease

Singh NK, Singh A, Varshney M, Agrawal R.

Curr Mol Med. 2023;23(9):889-900. doi: 10.2174/1566524023666230529093314.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias